Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,868 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diagnosis of Melanoma Clear all
Terminated Phase 2 Interventional Results available

Immunotherapy Study for Patients With Stage IV Melanoma

NCT02054520
View directory record Official record
Conditions
Stage IV Melanoma, Metastatic Melanoma
Interventions
HyperAcute®-Melanoma (HAM) Immunotherapy, Ipilimumab, Pembrolizumab, Nivolumab
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Niles, Illinois • Iowa City, Iowa • Westwood, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

NCT00462982
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 22, 2026, 1:31 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

NCT03958383
View directory record Official record
Conditions
Melanoma
Interventions
hu14.18-IL2, Radiation Therapy, Nivolumab, Ipilimumab
Biological · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 1:31 AM EDT
Terminated No phase listed Observational

Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy

NCT03407040
View directory record Official record
Conditions
Gastrointestinal Cancers, Breast Cancer, Pancreatic Cancer, Melanoma, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 22, 2026, 1:31 AM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

NCT07338968
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions
Interventions
Observational
Other
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
10
States / cities
Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 22, 2026, 1:31 AM EDT
Recruiting Phase 1 Interventional

A Study of VET3-TGI in Patients With Solid Tumors

NCT06444815
View directory record Official record
Conditions
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
Interventions
VET3-TGI, Atezolizumab
Drug
Lead sponsor
KaliVir Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Months to 24 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Dendritic Cell Activating Scaffold in Melanoma

NCT01753089
View directory record Official record
Conditions
Melanoma
Interventions
WDVAX
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 1:31 AM EDT
Completed No phase listed Observational

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

NCT03438279
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 22, 2026, 1:31 AM EDT
Terminated Phase 2 Interventional

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

NCT00121420
View directory record Official record
Conditions
Neoplasm Metastasis, Brain Neoplasms
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 22, 2026, 1:31 AM EDT
Active, not recruiting No phase listed Observational

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

NCT03728842
View directory record Official record
Conditions
Melanoma; Renal Cell Carcinoma
Interventions
Blood collection for laboratory studies, Data collection from medical record
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 1 Interventional Results available

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

NCT02032810
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Panobinostat, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

NCT00281957
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
sorafenib tosylate, tipifarnib, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
173
States / cities
Little Rock, Arkansas • Castro Valley, California • Fremont, California + 113 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 22, 2026, 1:31 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab + Relatlimab, rHuPH20
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 1:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Does the Aid of MelaFind Affect Clinical Management Decisions

NCT01387581
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
MELA Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Irvington, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 22, 2026, 1:31 AM EDT
Recruiting Phase 2 Interventional

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

NCT06627244
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Interventions
Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 1:31 AM EDT
Recruiting Phase 2 Interventional

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

NCT07237100
View directory record Official record
Conditions
Advanced Unresectable Melanoma, Metastatic Melanoma
Interventions
Mirdametinib
Drug
Lead sponsor
Kevin Kim, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

NCT00004244
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
recombinant interferon alfa, recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 22, 2026, 1:31 AM EDT
Terminated Phase 2 Interventional

A Study of Volociximab in Metastatic Melanoma

NCT00369395
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
volociximab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • La Jolla, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

NCT01072175
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, GSK1120212
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

NCT00436930
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous tumor cell vaccine, sargramostim, therapeutic autologous dendritic cells
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 22, 2026, 1:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709
View directory record Official record
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

NCT02570308
View directory record Official record
Conditions
Uveal Melanoma
Interventions
IMCgp100
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 22, 2026, 1:31 AM EDT